3.30Open3.30Pre Close0 Volume100 Open Interest7.50Strike Price0.00Turnover1016.36%IV-38.16%PremiumDec 20, 2024Expiry Date4.46Intrinsic Value100Multiplier8DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.4240Delta0.0833Gamma0.55Leverage Ratio-0.1123Theta-0.0013Rho-0.23Eff Leverage0.0018Vega
Revance Therapeutics Stock Discussion
Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement
Crown Laboratories and Revance Therapeutics (NASDAQ: RVNC) have announced an amended merger agreement where Crown will acquire all outstanding Revance shares for $3.10 per share in cash through a tender offer. The amendment comes after several developments, including Revance's settlement with Teoxane regarding distribution agreements and revised brand guidelines, which are expect...
📊⚡️📊
No comment yet